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Objectives. To evaluate the expression of hMLH1, p63, and MDM2 in Gorlin syndromeeassociated keratocystic odontogenic
tumors (SKOTs) and nonsyndromic keratocystic odontogenic tumors (NSKOTs).
Study Design. Seventeen primary NSKOTs, 17 SKOTs, and 8 recurrent NSKOTs were analyzed by using
immunohistochemistry.
Results. No significant differences in the hMLH1, p63, or MDM2 labeling indices were observed between groups (P ¼ .398;
P ¼ .232; P ¼ .426, respectively). Higher hMLH1 immunoexpression was found in the basal layer of primary NSKOTs. Most
KOTs exhibited p63 immunoexpression in the upper layers of the epithelium. MDM2 immunoexpression was observed in the
upper epithelial layers of SKOTs and recurrent NSKOTs.
Conclusion. It was not possible to correlate the immunoexpression of hMLH1, p63, and MDM2 in SKOTs and primary and
recurrent NSKOTs, suggesting that these proteins exert independent effects on the development of these groups of tumors.
(Oral Surg Oral Med Oral Pathol Oral Radiol 2015;120:52-57)Keratocystic odontogenic tumors (KOTs) are character-
ized by high rates of recurrence, inﬁltrative growth, and an
occasional association with nevoid basal cell carcinoma
syndrome (NBCCS).1-4 There are uncertainties as to
whether differences exist in the biologic behavior of Gorlin
syndromeeassociated KOTs (SKOTs) and nonsyndromic
KOTs (NSKOTs). In this respect, studies evaluating the
proteins involved in cell cycle and apoptosis,5-7 as well as
extracellular matrix components8 and proteases,7-11 sup-
port the existence of a different biologic behavior in
SKOTs and NSKOTs.
Protein p63 plays an important role in epithelial devel-
opment and in the proliferation of craniofacial structures.
In the human oral mucosa, p63 is restricted mainly to the
basal and parabasal layers of normal epithelium. Since
cystic odontogenic lesions are of epithelial origin, p63may
play an important role in the growth and progression of
these lesions.3
The mismatch repair (MMR) system plays an important
role in the maintenance of genetic stability.12,13 This sys-
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52arise during replication or as a result of DNA damage.
Mutations in four genes of the MMR system (MSH2,
hMLH1, MSH6, and PMS2) can inﬂuence the expression
of p63 and MDM-2 and predispose to a variety of
tumors.14-16
According to Castrili et al.,15 hMSH2 and hMLH1 are
expressed in human cells that are undergoing rapid
renewal; their reduced expression has been reported in
several tumors. MDM2 protein, together with p53,
participates in a complex regulatory network in response
to genotoxic stress. Thus, defects in this process are
related to the development of several types of cancer.
Other genes in the TP53 gene family, such as TP63 and
TP73, exert similar functions in tumor suppression,
apoptosis induction, and cell cycle control.3,5
Several studies have investigated the role of growth
factors, tumor suppressor genes, and oncogenes in the
onset and progression of KOT using immunohistochem-
istry.17-22 However, studies focusing on DNA repair
proteins are sparse, and there are no studies explaining the
participation of hMLH1 and its association with cell cycleStatement of Clinical Relevance
This study contributes to the understanding of the
biologic behavior of keratocystic odontogenic tumor
(KOT). The association of hMLH1, MDM2, and p63
has been identiﬁed in colon cancer and head and
neck carcinoma, and may provide additional insight
into understanding the mechanisms related to the
development and differences in behavior of KOT.
Table I. Properties of the primary antibodies
Clone Speciﬁcity Company Dilution Antigen retrieval Incubation
7 JUL P63 Santa Cruz Biotechnology,
Santa Cruz, CA
1:100 Citrate, pH 6.0
Pascal, 25’ at room
temperature
60 minutes
1 B10 MDM2 Novocastra Laboratories,
Benton Lane, Newcastle
upon Tyne, UK
1:50 Citrate, pH 6.0
Pascal, 15’ in microwave
60 minutes
G168-15 MLH1 Dako, Carpinteria, CA 1:50 Tris-EDTA, pH 9.0
Pascal, and 25’ at room
temperature
18 hours
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instability (MSI) is mainly caused by methylation-induced
silencing of the hMLH1 gene, we conducted the present
study to evaluate whether differences in the behavior of
KOTs are associated with changes in the expression of the
hMLH1 protein, in addition to p63 and MDM2, which
can be inﬂuenced by defects in the production of this
protein.MATERIALS AND METHODS
The study was approved by the Ethics Committee of the
Federal University of Rio Grande do Norte (UFRN),
Natal, Brazil (No. 246.800). Seventeen cases of primary
NSKOTs, 17 cases of SKOTs, and 8 cases of recurrent
NSKOTs were retrieved from the archives of the Patho-
logical Anatomy Services of the Departments of Oral
Pathology of UFRN and University of Fortaleza (UNI-
FOR) for the period between January 2005 and December
2012. The number of available institutional archival cases
deﬁned the size of the sample. The histologic diagnosis
was based on the third WHO classiﬁcation in all cases.23
All patients with Gorlin syndrome had been diagnosed
according to the criteria proposed by Evans et al.4 and
had multiple KOTs. The patients with sporadic KOTs
had single lesions and had been submitted to clinical
and radiographic assessment to exclude the presence of
other manifestations of Gorlin syndrome. All recurrent
lesions were treated with surgical enucleation and did
not correspond to recurrences from any of the primary
NSKOTs in this study. Serial 3-mm-thick sections
were cut from the tissue blocks and processed for
immunohistochemical analysis.Immunohistochemistry
The tissue sections were deparafﬁnized and immersed in
3% hydrogen peroxide to block endogenous peroxidase
activity. The sections were then washed in phosphate-
buffered saline (PBS). Antigen retrieval, antibody dilu-
tion, and clone type for p63, MDM2, and hMLH1 are
shown in Table I. After treatment with normal serum, the
sections were incubated with the primary antibodies in amoist chamber. Next, the sections were washed twice in
PBS and treated with a polymer-based complex
(Envision þ Dual Link System  HRP; Dako, Carpin-
teria, CA) at room temperature to bind the primary anti-
bodies. Peroxidase activity was visualized by immersing
the tissue sections in diaminobenzidine (Liquid DABþ;
Dako, Carpinteria, CA), which resulted in a brown reac-
tion product. Finally, the sections were counterstained
with Mayer’s hematoxylin and coverslipped. Sections of
colon carcinoma served as positive controls for all anti-
bodies. Samples treated as described above were used as
negative controls; however, the primary antibody was
replaced with a solution of bovine serum albumin in PBS.
Analysis of immunostaining
The tissue sections were examined in a blind fashion
under an Olympus CX31 light microscope (Olympus
Japan Co., Tokyo, Japan). The immunoexpression of
p63, MDM2, and hMLH1 was evaluated only in the
epithelial lining of KOTs by establishing the labeling
index. Brieﬂy, tissue sections were examined at 100
magniﬁcation to identify the area of the epithelial lining
containing the largest number of immunostained cells.
Next, 1000 epithelial cells were counted at 400
magniﬁcation in consecutive ﬁelds throughout all
epithelial layers. The p63, MDM2, and hMLH1 label-
ing indices are expressed as the percentage of immu-
nostained nuclei in relation to the total number of nuclei
counted. The intensity of the immunopositivity was not
considered in the samples of the present study.
Statistical analysis
The results were analyzed using the Statistical Package for
the Social Sciences (version 17.0; SPSS, Inc., Chicago,
IL). The nonparametric Kruskal-Wallis test was applied to
compare the percentage of p63-, MDM2-, and hMLH1-
immunopositive cells in the epithelial lining among
SKOTs, primary NSKOTs, and recurrent NSKOTs. The
Spearman correlation test was used to determine possible
correlations among the percentages of p63-, MDM2-, and
hMLH1-immunopositive cells. A level of signiﬁcance of
5% (P < .05) was adopted for all tests.
Table II. Parameters used for the calculation of the Kruskal-Wallis (KW) test for the evaluation of P63, MDM2, and
MLH1 labeling indices in primary nonsyndromic OKCs, recurrent nonsyndromic OKCs, and syndromic OKCs
Variable/group n Median Q25-Q75 Mean of ranks KW P
P63
Primary nonsyndromic OKC 17 57.00 49.35-66.55 21.18 2.924 .232
Recurrent nonsyndromic OKC 8 50.20 41.57-62.50 15.63
Syndromic OKC 17 61.70 56.00-71.45 24.59
MDM2
Primary nonsyndromic OKC 17 61.90 54.25-70.20 24.35 1.706 .426
Recurrent nonsyndromic OKC 8 54.35 40.27-64.97 18.13
Syndromic OKC 17 57.00 40.80-69.30 20.24
MLH1
Primary nonsyndromic OKC 17 52.20 40.85-68.15 20.74 1.844 .398
Recurrent nonsyndromic OKC 8 41.20 21.62-63.87 17.31
Syndromic OKC 17 56.90 50.90-62.65 24.24
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Immunoexpression of hMLH1 in the epithelial
component of KOT was positive in all cases analyzed.
In primary NSKOT, immunostaining for hMLH1 was
observed mainly in the basal epithelial layer (58.5%;
n ¼ 10). In SKOT and recurrent NSKOT, immuno-
staining was found in all layers of the epithelium, with
no predominance in a speciﬁc layer. The median
hMLH1 labeling index in the lining epithelium was
52.2 (range: 12.1-75.5) in the group of primary
NSKOT, 56.9 (range: 23.3-69.7) in SKOT, and 41.2
(range: 10.8-69.0) in recurrent NSKOT. There was no
signiﬁcant difference between groups (P ¼ .398,
Kruskal-Wallis test) (Table II).
Immunoexpression of p63 in the epithelial component
of KOT was positive in all cases analyzed. Immuno-
staining predominated in the upper layers of the epithe-
lium in 88.2% (n ¼ 15) of primary NSKOT (see
Figure 1B). In SKOT, immunoexpression was detected in
the basal and upper layers. Immunostaining predominated
in the upper epithelial layers in 75% of recurrent NSKOT.
The median p63 labeling index was 57.0 (range: 29.1-
74.3) in the group of primary NSKOT, 61.7 (range:
23.6-76.0) in SKOT, and 50.2 (range: 37.8-79.5) in
recurrent NSKOT. No signiﬁcant difference was
observed between groups (P ¼ .232, Kruskal-Wallis
test) (see Table II).
Immunoexpression of MDM2 in the epithelial
component of KOT was positive in all cases analyzed.
In primary NSKOT, 76% (n ¼ 13) exhibited immu-
nostaining in the basal and upper layers of the epithe-
lium. A predominance of immunostaining in the upper
epithelial layers was observed in SKOT and recurrent
NSKOT (see Figures 1G, 1H, and 1I). The median
MDM2 labeling index in the epithelial lining was
61.9 (range: 31.7-91.5) for primary NSKOT, 57.0
(range: 25.9-78.6) for SKOT, and 54.35 (range: 13.8-
75.9) for recurrent NSKOT. There was no signiﬁcantdifference between groups (P ¼ .426, Kruskal-Wallis
test) (see Table II).
The morphologic aspects of the lesions and details of
the immunostaining are presented in Figure 1 (A-L).
Spearman’s correlation test showed no signiﬁcant
correlations among the p63, MDM2, and hMLH1
labeling indices in the epithelial component of KOT
(P > .05).
DISCUSSION
The MMR repair system is important for maintaining
genomic stability, reducing DNA errors, and preventing
these errors from becoming ﬁxed mutations during cell
proliferation. MMR deﬁciencies are associated with a
higher risk of development of different types of cancer.25
Immunohistochemical analysis of the expression of the
hMSH2 and hMLH1 genes in tumors indicates that the
expression of these genes is typically lost in patients
with hereditary nonpolyposis colorectal cancer.13,14
Although the identiﬁcation of mutations in the PTCH
gene, among other factors, may support the classiﬁcation
of KOT as a neoplasm,2 there are no studies in the literature
that deﬁne the role of the MMR system in these lesions. In
the present study, no signiﬁcant difference in the hMLH1
labeling indices was observed among primary NSKOTs,
recurrent NSKOTs, and SKOTs (P > .05). Therefore,
possible differences in the biologic behaviors of these
lesions do not occur because of alterations in hMLH1
expression.
Castrili et al.15 showed that in ameloblastomas, hMSH2
and hMLH1 proteins are exclusively located in the nuclear
compartment of the outer layer of the tumor nests. The
restricted expression of hMSH2 and hMLH1 agrees with
the probable stem-cell nature of the outer cell compart-
ment from which inner stellate reticulum-like and squa-
mous cells originate. The authors suggested that the
development and progression of these tumors do not
depend on defects in the human MMR system.15
Fig. 1. A, Primary KOT (hematoxylin and eosin [H&E], 400). B, Syndrome KOT (H&E, 200). C, Recurrent KOT
(H&E, 200). D, hMLH1 immunoexpression in basal and suprabasal layers of a primary KOT (labeling index: 57,2); E, hMLH1
immunoexpression in basal and suprabasal layers of a syndromic KOT (labeling index: 41,8); F, hMLH1 immunoexpression in a
recurrent KOT observed mainly in superior epithelial layers (labeling index: 48,6) (Envision, 400). G, p63 immunoexpression in
suprabasal layers of a primary KOT (labeling index: 79,5); H, p63 immunoexpression in basal and suprabasal layers of a syndromic
KOT (labeling index: 69,5). I, p63 immunoexpression mainly in epithelial suprabasal layers of a recurrent KOT (labeling index:
49,1). (Envision, 400). J, Immunoexpression of MDM2 in all epithelial layers of a primary KOT (labeling index: 46,8); K,
Immunoexpression of MDM2 mainly in suprabasal layers of a syndromic KOT (labeling index: 41,6) L, Immunoexpression of
MDM2 mainly in epithelial suprabasal layers of a recurrent KOT (labeling index: 52,9) (Envision, 400).
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nated in the basal epithelial layer, whereas immunoex-
pression was seen in all of the epithelial layers of SKOT
and recurrent NSKOT. The present ﬁndings regarding
the location of hMLH1 immunoexpression may indicate
a more effective and consistent participation of the
MMR system in primary KOT, preventing the perpetu-
ation of DNA errors to the upper layers of the epithelium.
On the other hand, the immunoexpression of hMLH1 in
all of the epithelial layers of SKOT and recurrent
NSKOT suggests greater genomic instability in these
tumors compared with primary NSKOT. Moreover, the
slight reduction in the hMLH1 labeling index observedin cases of recurrent NSKOT might be related to the loss
of control of cell proliferation mechanisms, which ex-
plains the recurrence of these lesions.
The p63 gene expresses multiple isoforms. The most
common isoform is p63a, which encodes the p63 protein,
particularly DNp63a. This protein is abundant in the
highly proliferative basal cells of adult epithelial tissues,
including the oral epithelium. The p63 protein is also
highly expressed the embryonic ectoderm, being essential
in the differentiation of keratinocytes during embryonic
development. Moreover, p63 participation in the prolifer-
ation and differentiation of epithelial cells has been sug-
gested, since it is a homolog of the tumor suppressor p53.18
Fig. 2. Schematic diagram showing the association or pathway involving hMLH1, p63, and MDM-2.
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thought to contribute to the biologic proﬁle of these
tumors, playing a role in the regulation of epithelial
differentiation and favoring tumorigenesis.17
Overexpression of p63 has been observed in the
epithelial lining of KOT.3,17,18 In the present study,
immunoexpression of p63 was observed in all cases
studied, but there was no signiﬁcant difference in the
p63 labeling indices among primary NSKOT, recurrent
NSKOT, and SKOT (P > .05). Similarly, Atarbashi-
Moghadam et al.18 found no association between the
expression of this protein in KOT and clinical
features, such as recurrence and NBCCS.
With respect to the distribution of p63 immunoex-
pression in primary and recurrent NSKOT, higher
expression was observed in the upper layers of the
epithelium. The same has been reported in the literature
for KOT, regardless of the type of tumor (isolated,
recurrent, or syndromic).18-20 The immunoexpression
of this protein in more superﬁcial epithelial layers may
be related to disturbances in cell cycle control,
increasing the intrinsic growth potential. This fact
would explain the inﬁltrative and aggressive growth of
KOTs, as well as their higher recurrence rates,
compared with other odontogenic lesions.3 In general,high p63 immunoexpression in KOT may reﬂect the
immaturity of epithelial cells, favoring tumorigenesis,
and therefore supports the hypothesis of a neoplastic
origin of these tumors as well as the existence of a
suprabasal proliferative compartment.17
Inmost human cancers, the tumor suppressor function of
p53 is compromised by mutations in the TP53 gene or by
partial inhibition of the regulation of this protein. Under
normal conditions, p53 levels are precisely regulated by
MDM2.21 In the present study,MDM2 immunoexpression
was observed in all KOT cases, in contrast to the literature,
which reports immunoexpression in only 80% of the cases
studied,21 or even the complete absence of this marker in
KOT.24 However, high MDM2 immunoreactivity in
KOT cases compared with other odontogenic tumors has
also been reported.22 Furthermore, in the present study,
MDM2 immunoexpression predominated in the middle
and upper compartments. This ﬁnding agrees with the
observations of Shariﬁ-Sistani et al.,21 who compared the
immunoexpression of MDM2 and p53 between KOT and
ameloblastoma and found a correlation between these
proteins, that is, an increase in one protein would lead to
an increase in the other. The authors suggested that the
increased immunoexpression of MDM2 in some tumors
would not be able to reduce the amount of mutated p53.21
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shown to be mediated by the interaction with MMR genes
and proteins.14,26 DNA mismatch repair genes also play a
role in the development of sporadic human neoplasms.
Advances in our understanding of mismatch repair deﬁ-
ciency have important applications. Furthermore, the main
function of MDM2 is to negatively regulate p53 by bind-
ing directly to the latter. This binding results in the for-
mation of the MDM2/p53 complex, which inhibits the
transcription activity of p53 and induces its degradation.26
However, no correlation among the hMLH1, p63, and
MDM2 labeling indices was observed in the present
study, suggesting that these proteins exert independent
effects on the development of these tumors; in Figure 2,
we have presented the pathway involving hMLH1, p63,
and MDM-2. Future studies that include different mem-
bers of DNAmismatch repair genes (hMSH2, hMSH6, and
hPMS2) should be performed to further elucidate their role
in the pathogenesis of these lesions.REFERENCES
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